A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards

  • Nicholas M. Mordwinkin
  • Paul W. Burridge
  • Joseph C. Wu
Article

Abstract

Drug attrition rates have increased in past years, resulting in growing costs for the pharmaceutical industry and consumers. The reasons for this include the lack of in vitro models that correlate with clinical results and poor preclinical toxicity screening assays. The in vitro production of human cardiac progenitor cells and cardiomyocytes from human pluripotent stem cells provides an amenable source of cells for applications in drug discovery, disease modeling, regenerative medicine, and cardiotoxicity screening. In addition, the ability to derive human-induced pluripotent stem cells from somatic tissues, combined with current high-throughput screening and pharmacogenomics, may help realize the use of these cells to fulfill the potential of personalized medicine. In this review, we discuss the use of pluripotent stem cell-derived cardiomyocytes for drug discovery and cardiotoxicity screening, as well as current hurdles that must be overcome for wider clinical applications of this promising approach.

Keywords

Pluripotent stem cells Cardiovascular disease Toxicity screening Drug discovery 

Notes

Acknowledgments

We would like to acknowledge the funding support from NIH R01 HL113006, Fondation Leducq 11CVD02, CIRM RB3-05129 (JCW), and AHA Postdoctoral Fellowship (PWB).

Disclosures

None

References

  1. 1.
    Gu, Q., Dillon, C. F., & Burt, V. L. (2010). Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief, 42, 1–8.PubMedGoogle Scholar
  2. 2.
    Roger, V. L., et al. (2012). Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation, 125(1), e2–e220.PubMedCrossRefGoogle Scholar
  3. 3.
    Takahashi, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872.PubMedCrossRefGoogle Scholar
  4. 4.
    Yu, J., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.PubMedCrossRefGoogle Scholar
  6. 6.
    Park, I. H., et al. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451(7175), 141–146.PubMedCrossRefGoogle Scholar
  7. 7.
    Ellison, G. M., et al. (2007). Myocyte death and renewal: modern concepts of cardiac cellular homeostasis. Nature Clinical Practice. Cardiovascular Medicine, 4(Suppl 1), S52–S59.PubMedCrossRefGoogle Scholar
  8. 8.
    MacLellan, W. R., & Schneider, M. D. (2000). Genetic dissection of cardiac growth control pathways. Annual Review of Physiology, 62, 289–319.PubMedCrossRefGoogle Scholar
  9. 9.
    Nadal-Ginard, B., et al. (2003). A matter of life and death: cardiac myocyte apoptosis and regeneration. The Journal of Clinical Investigation, 111(10), 1457–1459.PubMedGoogle Scholar
  10. 10.
    Torella, D., et al. (2006). Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nature Clinical Practice. Cardiovascular Medicine, 3(Suppl 1), S8–S13.PubMedCrossRefGoogle Scholar
  11. 11.
    Boudoulas, K. D., & Hatzopoulos, A. K. (2009). Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Disease Models & Mechanisms, 2(7–8), 344–358.CrossRefGoogle Scholar
  12. 12.
    Habib, M., Caspi, O., & Gepstein, L. (2008). Human embryonic stem cells for cardiomyogenesis. Journal of Molecular and Cellular Cardiology, 45(4), 462–474.PubMedCrossRefGoogle Scholar
  13. 13.
    Laflamme, M. A., & Murry, C. E. (2005). Regenerating the heart. Nature Biotechnology, 23(7), 845–856.PubMedCrossRefGoogle Scholar
  14. 14.
    Murry, C. E., Field, L. J., & Menasche, P. (2005). Cell-based cardiac repair: reflections at the 10-year point. Circulation, 112(20), 3174–3183.PubMedCrossRefGoogle Scholar
  15. 15.
    Hyun, I., et al. (2008). New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell, 3(6), 607–609.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldring, C. E., et al. (2011). Assessing the safety of stem cell therapeutics. Cell Stem Cell, 8(6), 618–628.PubMedCrossRefGoogle Scholar
  17. 17.
    Lian, Q., et al. (2010). Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases. Thrombosis and Haemostasis, 104(1), 39–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Tanaka, T., et al. (2009). In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochemical and Biophysical Research Communications, 385(4), 497–502.PubMedCrossRefGoogle Scholar
  19. 19.
    Yokoo, N., et al. (2009). The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochemical and Biophysical Research Communications, 387(3), 482–488.PubMedCrossRefGoogle Scholar
  20. 20.
    Kannankeril, P. J., & Roden, D. M. (2007). Drug-induced long QT and torsade de pointes: recent advances. Current Opinion in Cardiology, 22(1), 39–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. Journal of Internal Medicine, 259(1), 70–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Thomsen, M. B., et al. (2006). Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacology and Therapeutics, 112(1), 150–170.PubMedCrossRefGoogle Scholar
  23. 23.
    Miller, R. A., et al. (2008). Efficient array-based identification of novel cardiac genes through differentiation of mouse ESCs. PLoS One, 3(5), e2176.PubMedCrossRefGoogle Scholar
  24. 24.
    Cao, F., et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One, 3(10), e3474.PubMedCrossRefGoogle Scholar
  25. 25.
    Varlet, I., Collignon, J., & Robertson, E. J. (1997). Nodal expression in the primitive endoderm is required for specification of the anterior axis during mouse gastrulation. Development, 124(5), 1033–1044.PubMedGoogle Scholar
  26. 26.
    Conlon, F. L., et al. (1994). A primary requirement for nodal in the formation and maintenance of the primitive streak in the mouse. Development, 120(7), 1919–1928.PubMedGoogle Scholar
  27. 27.
    Ben-Haim, N., et al. (2006). The nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Developmental Cell, 11(3), 313–323.PubMedCrossRefGoogle Scholar
  28. 28.
    Brennan, J., et al. (2001). Nodal signalling in the epiblast patterns the early mouse embryo. Nature, 411(6840), 965–969.PubMedCrossRefGoogle Scholar
  29. 29.
    Winnier, G., et al. (1999). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes & Development, 9(17), 2105–2116.CrossRefGoogle Scholar
  30. 30.
    Liu, P., et al. (1999). Requirement for Wnt3 in vertebrate axis formation. Nature Genetics, 22(4), 361–365.PubMedCrossRefGoogle Scholar
  31. 31.
    Pearce, J. J., & Evans, M. J. (1999). Mml, a mouse Mix-like gene expressed in the primitive streak. Mechanisms of Development, 87(1–2), 189–192.PubMedCrossRefGoogle Scholar
  32. 32.
    Wilkinson, D. G., Bhatt, S., & Herrmann, B. G. (1990). Expression pattern of the mouse T gene and its role in mesoderm formation. Nature, 343(6259), 657–659.PubMedCrossRefGoogle Scholar
  33. 33.
    Blum, M., et al. (1992). Gastrulation in the mouse: the role of the homeobox gene goosecoid. Cell, 69(7), 1097–1106.PubMedCrossRefGoogle Scholar
  34. 34.
    Ciruna, B. G., & Rossant, J. (1999). Expression of the T-box gene Eomesodermin during early mouse development. Mechanisms of Development, 81(1–2), 199–203.PubMedCrossRefGoogle Scholar
  35. 35.
    Ema, M., Takahashi, S., & Rossant, J. (2006). Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. Blood, 107(1), 111–117.PubMedCrossRefGoogle Scholar
  36. 36.
    Takakura, N., et al. (1997). PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohistostaining using the monoclonal anti-mouse PDGFR alpha antibody APA5. Journal of Histochemistry and Cytochemistry, 45(6), 883–893.PubMedCrossRefGoogle Scholar
  37. 37.
    Sakurai, H., et al. (2006). In vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility. Stem Cells, 24(3), 575–586.PubMedCrossRefGoogle Scholar
  38. 38.
    Tam, P. P., & Behringer, R. R. (1997). Mouse gastrulation: the formation of a mammalian body plan. Mechanisms of Development, 68(1–2), 3–25.PubMedCrossRefGoogle Scholar
  39. 39.
    Buckingham, M., Meilhac, S., & Zaffran, S. (2005). Building the mammalian heart from two sources of myocardial cells. Nature Reviews Genetics, 6(11), 826–835.PubMedCrossRefGoogle Scholar
  40. 40.
    McKinsey, T. A., Zhang, C. L., & Olson, E. N. (2002). MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends in Biochemical Sciences, 27(1), 40–47.PubMedCrossRefGoogle Scholar
  41. 41.
    Antonini, G., et al. (2000). Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology, 55(8), 1207–1209.PubMedCrossRefGoogle Scholar
  42. 42.
    Belaguli, N. S., et al. (2000). Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Molecular and Cellular Biology, 20(20), 7550–7558.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang, Q., et al. (2001). Comparative studies on the expression patterns of three troponin T genes during mouse development. Anatomical Record, 263(1), 72–84.PubMedCrossRefGoogle Scholar
  44. 44.
    Hescheler, J., et al. (1997). Embryonic stem cells: a model to study structural and functional properties in cardiomyogenesis. Cardiovascular Research, 36(2), 149–162.PubMedCrossRefGoogle Scholar
  45. 45.
    Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes & Development, 19(10), 1129–1155.CrossRefGoogle Scholar
  46. 46.
    Boheler, K. R., et al. (2005). Cardiomyocytes derived from embryonic stem cells. Methods in Molecular Medicine, 108, 417–435.PubMedGoogle Scholar
  47. 47.
    Boheler, K. R., et al. (2002). Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circulation Research, 91(3), 189–201.PubMedCrossRefGoogle Scholar
  48. 48.
    Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.PubMedCrossRefGoogle Scholar
  49. 49.
    Wernig, M., et al. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 448(7151), 318–324.PubMedCrossRefGoogle Scholar
  50. 50.
    Novak, A., et al. (2010). Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cellular Reprogramming, 12(6), 665–678.PubMedCrossRefGoogle Scholar
  51. 51.
    Haase, A., et al. (2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell, 5(4), 434–441.PubMedCrossRefGoogle Scholar
  52. 52.
    Li, C., et al. (2009). Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Human Molecular Genetics, 18(22), 4340–4349.PubMedCrossRefGoogle Scholar
  53. 53.
    Jia, F., et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nature Methods, 7(3), 197–199.PubMedCrossRefGoogle Scholar
  54. 54.
    Fusaki, N., et al. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(8), 348–362.PubMedCrossRefGoogle Scholar
  55. 55.
    Yu, J., et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324(5928), 797–801.PubMedCrossRefGoogle Scholar
  56. 56.
    Burridge, P. W., et al. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell, 10(1), 16–28.PubMedCrossRefGoogle Scholar
  57. 57.
    Keller, G. M. (1995). In vitro differentiation of embryonic stem cells. Current Opinion in Cell Biology, 7(6), 862–869.PubMedCrossRefGoogle Scholar
  58. 58.
    Mummery, C., et al. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation, 107(21), 2733–2740.PubMedCrossRefGoogle Scholar
  59. 59.
    Nakano, T., Kodama, H., & Honjo, T. (1994). Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science, 265(5175), 1098–1101.PubMedCrossRefGoogle Scholar
  60. 60.
    Murry, C. E., & Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell, 132(4), 661–680.PubMedCrossRefGoogle Scholar
  61. 61.
    Nishikawa, S. I., et al. (1998). Progressive lineage analysis by cell sorting and culture identifies FLK1 + VE-cadherin + cells at a diverging point of endothelial and hemopoietic lineages. Development, 125(9), 1747–1757.PubMedGoogle Scholar
  62. 62.
    Anonymous. (2006). The bitterest pill. Nature, 444(7119), 532–533.CrossRefGoogle Scholar
  63. 63.
    Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–715.PubMedCrossRefGoogle Scholar
  64. 64.
    Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Reviews. Drug Discovery, 10(2), 111–126.PubMedCrossRefGoogle Scholar
  65. 65.
    Lawrence, C. L., et al. (2008). In vitro models of proarrhythmia. British Journal of Pharmacology, 154(7), 1516–1522.PubMedCrossRefGoogle Scholar
  66. 66.
    Ma, J., et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. American Journal of Physiology - Heart and Circulatory Physiology, 301(5), H2006–H2017.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhang, J., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30–e41.PubMedCrossRefGoogle Scholar
  68. 68.
    Braam, S. R., et al. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research, 4(2), 107–116.PubMedCrossRefGoogle Scholar
  69. 69.
    Chapin, R. E., & Stedman, D. B. (2009). Endless possibilities: stem cells and the vision for toxicology testing in the 21st century. Toxicological Sciences, 112(1), 17–22.PubMedCrossRefGoogle Scholar
  70. 70.
    Davila, J. C., et al. (2004). Use and application of stem cells in toxicology. Toxicological Sciences, 79(2), 214–223.PubMedCrossRefGoogle Scholar
  71. 71.
    Ebert, A. D., Liang, P., & Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of Cardiovascular Pharmacology, 60(4), 408–416.PubMedCrossRefGoogle Scholar
  72. 72.
    Dick, E., et al. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochemical Society Transactions, 38(4), 1037–1045.PubMedCrossRefGoogle Scholar
  73. 73.
    Caspi, O., et al. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells and Development, 18(1), 161–172.PubMedCrossRefGoogle Scholar
  74. 74.
    McNeish, J. (2004). Embryonic stem cells in drug discovery. Nature Reviews. Drug Discovery, 3(1), 70–80.PubMedCrossRefGoogle Scholar
  75. 75.
    Pollard, C. E., Valentin, J. P., & Hammond, T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. British Journal of Pharmacology, 154(7), 1538–1543.PubMedCrossRefGoogle Scholar
  76. 76.
    Brimecombe, J. C., Kirsch, G. E., & Brown, A. M. (2009). Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability. Journal of Pharmacological and Toxicological Methods, 59(1), 29–34.PubMedCrossRefGoogle Scholar
  77. 77.
    Lahti, A. L., et al. (2012). Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Disease Models & Mechanisms, 5(2), 220–230.CrossRefGoogle Scholar
  78. 78.
    Chaudhary, K. W., et al. (2006). Embryonic stem cells in predictive cardiotoxicity: laser capture microscopy enables assay development. Toxicological Sciences, 90(1), 149–158.PubMedCrossRefGoogle Scholar
  79. 79.
    Mohr, J. C., et al. (2010). The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. Biomaterials, 31(7), 1885–1893.PubMedCrossRefGoogle Scholar
  80. 80.
    Rana, P., et al. (2012). Characterization of human induced pluripotent stem cell derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicological Sciences, 130(1), 117–131.PubMedCrossRefGoogle Scholar
  81. 81.
    Takei, S., et al. (2009). Bone morphogenetic protein-4 promotes induction of cardiomyocytes from human embryonic stem cells in serum-based embryoid body development. American Journal of Physiology - Heart and Circulatory Physiology, 296(6), H1793–H1803.PubMedCrossRefGoogle Scholar
  82. 82.
    Reppel, M., et al. (2005). The electrocardiogram of human embryonic stem cell-derived cardiomyocytes. Journal of Electrocardiology, 38(4 Suppl), 166–170.PubMedCrossRefGoogle Scholar
  83. 83.
    Harmer, A. R., et al. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. Journal of Pharmacological and Toxicological Methods, 57(1), 30–41.PubMedCrossRefGoogle Scholar
  84. 84.
    Sanchez-Freire, V., et al. (2012). Microfluidic single-cell real-time PCR for comparative analysis of gene expression patterns. Nature Protocols, 7(5), 829–838.PubMedCrossRefGoogle Scholar
  85. 85.
    Muzikant, A. L., & Penland, R. C. (2002). Models for profiling the potential QT prolongation risk of drugs. Current Opinion in Drug Discovery & Development, 5(1), 127–135.Google Scholar
  86. 86.
    Meyer, T., et al. (2004). QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay and Drug Development Technologies, 2(5), 507–514.PubMedCrossRefGoogle Scholar
  87. 87.
    Sun, N., et al. (2012). Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Science Translational Medicine, 4(130), 130ra47.PubMedCrossRefGoogle Scholar
  88. 88.
    Cubeddu, L. X. (2003). QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American Journal of Therapy, 10(6), 452–457.CrossRefGoogle Scholar
  89. 89.
    Drici, M. D., & Clement, N. (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safety, 24(8), 575–585.PubMedCrossRefGoogle Scholar
  90. 90.
    Yang, L., et al. (2008). Human cardiovascular progenitor cells develop from a KDR + embryonic-stem-cell-derived population. Nature, 453(7194), 524–528.PubMedCrossRefGoogle Scholar
  91. 91.
    Kiskinis, E., & Eggan, K. (2010). Progress toward the clinical application of patient-specific pluripotent stem cells. The Journal of Clinical Investigation, 120(1), 51–59.PubMedCrossRefGoogle Scholar
  92. 92.
    Schulz, T. C., et al. (2007). A large-scale proteomic analysis of human embryonic stem cells. BMC Genomics, 8, 478.PubMedCrossRefGoogle Scholar
  93. 93.
    Thomas, R. J., et al. (2009). Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnology and Bioengineering, 102(6), 1636–1644.PubMedCrossRefGoogle Scholar
  94. 94.
    Anderson, D., et al. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Molecular Therapy, 15(11), 2027–2036.PubMedCrossRefGoogle Scholar
  95. 95.
    Huber, I., et al. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. The FASEB Journal, 21(10), 2551–2563.CrossRefGoogle Scholar
  96. 96.
    Xu, X. Q., et al. (2008). Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy, 10(4), 376–389.PubMedCrossRefGoogle Scholar
  97. 97.
    Rajala, K., et al. (2010). A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS One, 5(4), e10246.PubMedCrossRefGoogle Scholar
  98. 98.
    Rodriguez-Piza, I., et al. (2010). Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells, 28(1), 36–44.PubMedGoogle Scholar
  99. 99.
    Narsinh, K. H., et al. (2011). Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. The Journal of Clinical Investigation, 121(3), 1217–1221.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Nicholas M. Mordwinkin
    • 1
    • 2
    • 3
  • Paul W. Burridge
    • 1
    • 2
    • 3
  • Joseph C. Wu
    • 1
    • 2
    • 3
  1. 1.Department of Medicine (Division of Cardiology)Stanford UniversityStanfordUSA
  2. 2.Institute for Stem Cell Biology and Regenerative MedicineStanford UniversityStanfordUSA
  3. 3.Stanford Cardiovascular InstituteStanford UniversityStanfordUSA

Personalised recommendations